A Clinico-Epidemiological Study of Neurofibromatosis Type 1 and Its Relation to Quality of Life: A Cross-Sectional Study From India

Aditi Mahajan 1, Milind Patvekar 1, Samruddhi Lote 1, Mahendra Singh Deora 1, Divya Poulose 1, Jaya Madhurya Gogineni 1, Krish Panikar 2, Biswajit Chaklader 3

Abstract

Introduction: Neurofibromatosis type 1 (NF1) is an inherited neuroectodermal abnormality with multisystem effects, which can have heavy psychological and physical burdens, especially in countries like India, wherein skin disease is significantly stigmatized. This study was performed to understand the clinical and epidemiological trends of NF1 at a tertiary care center in India and evaluate the association between clinical severity and quality of life in these patients.

Methods: We conducted a cross-sectional study of 40 patients with NF1 over a period of two years at a tertiary hospital in western India. After obtaining consent, demographic and clinical information was collected from the patients and recorded in a pre-designed proforma. Quality of life was assessed by a validated Dermatology Life Quality Index (DLQI) questionnaire in languages understood by the patients and subsequently analyzed.

Results: This study included 40 patients at a mean age of 28.6 years, with a slight male predominance. The most frequently occurring lesions were café-au-lait macules, followed by neurofibromas and intertriginous freckling. The mean DLQI score was 12.35, implying a large effect on most patients’ lives. Questions related to self-consciousness, embarrassment, and the influence of skin lesions on clothing choices had the highest scores, indicating a significant effect on social perception.

Conclusion: NF1 has a profound impact on a patient’s quality of life, as evidenced by the high DLQI scores in our patient cohort. The early identification and management of such patients can help prevent further deterioration of their quality of life.

Introduction

Neurofibromatosis type 1 (NF1) is an inherited neuroectodermal disease, primarily defined by the presence of six or more café-au-lait macules, intertriginous freckles, two or more neurofibromas, Lisch nodules, bony defects like sphenoid dysplasia, and optic gliomas. It is an autosomal dominant condition with an estimated prevalence of one in 2500-3300 births, with 50% of cases occurring due to sporadic gene mutations [1]. Dermatological manifestations appear early in life and progress with age, but neurological features usually present at a later age [2]. The diagnosis of this condition is usually clinical, with genetic testing rarely being necessary. The cost and accessibility of genetic analysis, which is only available in a few selected tertiary care centers, are major barriers to the research and management of this disease in developing countries like India.

NF1 is a chronic disease that puts a large amount of stress on patients, which adversely impacts their identity, mental well-being, self-confidence, and social relationships. Patients with incurable disorders must cope with multiple impediments to attain a feasible level of health, as well as adequate physical, intellectual, and social functioning [3]. Mental disorders like anxiety, personality disorders, depression, and suicidal tendencies are common in individuals with NF1 [4]. In severe cases, the persistence of cognitive impairment into adulthood hinders a patient’s vocational performance, thereby hampering their quality of life (QoL) [5]. In a study of NF1 patients in Iran, Foji et al. found that NF1 affected all aspects of the patient’s life. In particular, perceived social alienation and difficulties regarding marriage and childbirth were present due to apprehensions regarding disease transmission to their progeny [6]. In short, dermatological diseases are a major contributor to the burden of non-fatal disease globally and influence different aspects of an individual’s life [7]. Since the initial presentation of NF1 is mainly confined to the skin, patients usually...
consult dermatologists first. Thus, dermatologists must especially be aware of the options for screening, genetic counseling, and prenatal diagnosis of the disease. A multidisciplinary approach must be adopted for the management of these patients [8-10].

In 1994, Finlay et al. developed the Dermatology Life Quality Index (DLQI) [11,12]. This is a 10-item questionnaire that covers six domains, specifically regarding symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. In this study, we aimed to evaluate the psychological impact of NF1 on an Indian population, gauge their QoL, and understand the extent of disease burden by using the DLQI questionnaire.

Materials And Methods

Study design

This cross-sectional study enrolled 40 patients with NF1 reporting to the dermatology clinic in a tertiary hospital in western India, across a span of 24 months. The study was approved by the Research and Recognition Committee of Dr. D. Y. Patil Medical College, Hospital and Research Centre (approval number: IESC/PGS/2019/43).

Data collection

Socio-demographic and clinical information was obtained from the patients after due consent and documented in a pre-designed proforma. Clinical history and examination of patients were followed by evaluation of their QoL, using a validated DLQI questionnaire (10-item questionnaire) in languages comprehensible to them.

Inclusion and exclusion criteria

All individuals clinically suspected to have NF1 as per the criteria of the National Institute of Health were included in the study. Patients not consenting to participate were excluded from the study. Age, sex, disease duration, and the presence or absence of any other major illnesses were not considered for inclusion or exclusion.

DLQI questionnaire

Each question of the DLQI questionnaire has five possible responses: “not relevant,” “not at all,” “a little,” “a lot,” or “very much,” which are scored as 0, 0, 1, 2, and 3, respectively. Question 7 is scored differently, with “prevented work or studying” being given a score of 5 [13]. The DLQI questionnaire is presented in the Appendix.

The final DLQI score was calculated as the sum of the scores of all questions, which has a range of 0-30. DLQI scores of 0-1, 2-5, 6-10, 11-20, and 21-30, respectively, correspond to having no, small, moderate, very large, and extremely large effect on the patient’s life.

Statistical analysis

Data were entered in Microsoft Excel (Microsoft Corporation, Redmond, WA) and analyzed using the Statistical Package for the Social Sciences (SPSS) software version 20 (IBM Corp., Armonk, NY). Categorical variables were expressed in terms of frequency and percentage, whereas continuous variables were expressed as the mean and standard deviation (SD). For qualitative variables, the percentage and chi-square test were performed. Karl Pearson coefficient of correlation was also performed. A two-tailed probability value of 0.05 or less was considered statistically significant.

Results

This study included 40 patients with an age range of 6-65 (mean: 28.6) years, including 23 (57.5%) males and 17 (42.5%) females (Table 1). A family history of NF1 was positive in 19 (47.5%) patients, with seven (17.5%) patients reporting consanguineous marriage of their parents. Café-au-lait macules and neurofibromas, which were both seen in 38 (95%) patients, were the most commonly occurring lesions. Intertriginous freckling was seen in 28 (70%) patients, Lisch nodules in 19 (47.5%), plexiform neurofibromas in 15 (37.5%), and optic nerve tumors in one (2.5%) patient.
The mean DLQI score was 12.35 ± 7.73, which reflects a significant degree of impact on the QoL of most patients. Table 2 demonstrates the various categories of DLQI scores obtained in our cohort.

Table 3 depicts the mean scores of answers to individual questions of the DLQI questionnaire. Impairment of QoL, evaluated via the DLQI questionnaire, revealed that question 2 (i.e., "Over the last week, how embarrassed or self-conscious have you been because of your skin?") had the highest mean score of 1.9, followed by question 4 (i.e., "Over the last week, how much has your skin influenced the clothes you wear?"), with a score of 1.85. On the other hand, question 6, related to difficulties in playing any sports, had the lowest average score of 0.45.
| Question | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | Total |
|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|
| Mean     | 1.9 | 0.65 | 1.86 | 0.95 | 0.45 | 1.8 | 1.43 | 0.87 | 1.45 | 12.35 |
| SD       | 0.894 | 0.943 | 0.823 | 0.989 | 1.047 | 0.705 | 0.891 | 1.053 | 0.921 | 7.738 |

**TABLE 3: Mean scores of individual questions of DLQI.**

DLQI, Dermatology Life Quality Index.

Tables 4, 5 demonstrate the comparison between the various demographic and clinical factors and DLQI categories. Age, presence of café-au-lait macules, Lisch nodules, freckling, and plexiform neurofibromas had a significant negative correlation with QoL (p < 0.05). Gender, family history of the disease, and parental consanguinity did not have a significant correlation with QoL.
| Gender | DLQI categories | P-value |
|--------|-----------------|---------|
|        | Small effect    | Moderate effect | Very large effect | Extremely large effect | Total |        |
| Male   | 7               | 6         | 7               | 3                 | 23    | p = 0.35 |
|        | 30.43%          | 26.10%    | 30.43%          | 13.04%            | 100.00% |
| Female | 3               | 5         | 3               | 6                 | 17    |
|        | 17.65%          | 29.41%    | 17.65%          | 35.29%            | 100.00% |

| Age    | DLQI categories | P-value |
|--------|-----------------|---------|
|        | Small effect    | Moderate effect | Very large effect | Extremely large effect | Total |        |
| 10     | 2               | 0         | 0               | 0                 | 2     | p = 0.0015 |
|        | 18.75%          | 50.00%    | 12.50%          | 18.75%            | 100.00% |
| 31-40  | 1               | 0         | 3               | 4                 | 2     |
|        | 25.00%          | 0.00%     | 0.00%           | 75.00%            | 100.00% |
| 41-50  | 1               | 0         | 4               | 3                 | 8     |
|        | 12.50%          | 0.00%     | 50.00%          | 37.50%            | 100.00% |
| >51    | 0               | 0         | 1               | 0                 | 1     |

| Family history of NF1 | DLQI categories | P-value |
|-----------------------|-----------------|---------|
| Positive              | Small effect    | Moderate effect | Very large effect | Extremely large effect | Total | p = 0.17 |
| 3                     | 4               | 5         | 7                | 19                |
| 15.79%                | 21.05%          | 26.32%    | 36.84%           | 100.00%           |
| Negative              | 7               | 7         | 5                | 2                 | 21    |
| 33.33%                | 33.33%          | 23.81%    | 9.53%            | 100.00%           |

| Consanguineous marriage of parents | DLQI categories | P-value |
|-----------------------------------|-----------------|---------|
| Present                           | Small effect    | Moderate effect | Very large effect | Extremely large effect | Total | p = 0.34 |
| 0                                 | 2               | 2         | 3                | 7                 |
| 0.00%                             | 28.57%          | 28.57%    | 42.86%           | 100.00%           |
| Absent                            | 10              | 9         | 8                | 6                 | 33    |
| 30.30%                            | 27.28%          | 24.24%    | 18.18%           | 100.00%           |

**TABLE 4: Comparison between demographic factors and DLQI categories.**

DLQI, Dermatology Life Quality Index; NF1, neurofibromatosis type 1.
| DLQI categories | P-value | Small effect | Moderate effect | Very large effect | Extremely large effect | Total |
|-----------------|---------|--------------|-----------------|-------------------|------------------------|-------|
| CALMS 10        |         | 3            | 2               | 0                 | 0                      | 5     |
| 11-25           |         | 6            | 6               | 1                 | 2                      | 15    |
| 26-50           |         | 0            | 3               | 6                 | 4                      | 13    |
| >50             |         | 0            | 0               | 2                 | 3                      | 5     |
| CALMS Total     | p < 0.0001 | 0.00%       | 40.00%          | 0.00%             | 13.33%                 | 100.00% |
| NFs 10          |         | 6            | 1               | 1                 | 0                      | 8     |
| 11-25           |         | 3            | 8               | 5                 | 4                      | 20    |
| 26-50           |         | 0            | 1               | 2                 | 3                      | 6     |
| >50             |         | 0            | 0               | 2                 | 2                      | 4     |
| NFs Total       | p < 0.01 | 75.00%       | 12.50%          | 12.50%            | 0.00%                  | 100.00% |
| Freckling Present in |         | 3            | 8               | 8                 | 9                      | 28    |
| 11.71%          | p < 0.001 | 28.57%       | 28.57%          | 32.15%            | 100.00%                |
| Lisch nodules Present in |         | 3            | 3               | 7                 | 6                      | 19    |
| 15.79%          | p = 0.007 | 15.79%       | 36.84%          | 31.58%            | 100.00%                |
| Plexiform NFs Present in |         | 0            | 1               | 6                 | 8                      | 15    |
| 0.00%           | p = 0.006 | 6.67%        | 40.00%          | 53.33%            | 100.00%                |

**TABLE 5: Comparison between clinical features and DLQI categories.**

DLQI, Dermatology Life Quality Index; CALMS, café-au-lait macules; NFs- neurofibromas.

**Discussion**

Our study cohort had a slight male predominance, which was also seen in a study by Purkait et al. on patients with neurocutaneous syndromes [2]. The most frequently occurring lesions in our study were café-au-lait macules, seen in 95% of patients, which had a similar prevalence of 93% in a study by Lakshmanan et
al. on NF1 patients in South India. Furthermore, their study demonstrated freckling in 90% of patients, whereas in our group, this occurred in 70%. A family history of NF1 was positive in 47.5% of our patients, in contrast to 33% of patients in their study [14]. Cutaneous neurofibromas were seen in 95% of our patients, similar to the findings of Lakshmanan et al. and Wolkenstein et al., with an occurrence of 96.6% and 91%, respectively [10,14].

The presence of plexiform neurofibromas in our study was comparable to that of a study by Huson et al. (37.5% vs. 32%, respectively) [15]. On the other hand, Lisch nodules were present in 47.5% of patients in our study, which is lower than that in a study from Northwest England and a study by Friedman et al. (63% and 57%, respectively) [16,17].

The mean DLQI was 12.35 ± 7.73, with higher QoL impairment in females (14 ± 8.66) than in males (11.13 ± 6.72). Higher DLQI scores were observed with more extensive skin involvement, female gender, and the presence of plexiform neurofibromas. Upon analysis of DLQI scores, NF1 had no effect in zero cases but had a small, moderate, very large, and extremely large effect in 10 (25%), 11 (27.5%), 10 (25%), and nine (22.5%) patients, respectively.

Similar studies from Italy and America demonstrated that patients with more visible lesions had a greater impact on the emotional aspect of their QoL [18,19]. A study from Brazil concluded that patients were significantly concerned about transmitting the disease to their progeny and expressed difficulties in obtaining appropriate treatment [20]. Various studies on the QoL of NF1 patients done in a few countries also reported a negative effect on QoL across multiple aspects of life [21,22]. A Canadian study of 176 patients reported that patients’ mental well-being and overall QoL were influenced greatly by their perceived physical appearance [23].

The presence of café-au-lait macules, Lisch nodules, plexiform neurofibromas, and freckling had a significant negative correlation with QoL (P < 0.05). Individual questions of the DLQI questionnaire demonstrated the highest mean scores for questions 2 and 4 (1.9 and 1.85, respectively), followed by question 10 (1.8), indicating that self-consciousness, embarrassment, choice of clothing, and time taken by treatment were aspects of their lives most affected by the disease. Questions 3 and 6, pertaining to difficulty in playing sports and shopping/gardening, had the lowest mean scores, signifying a lower impact on these spheres of a patient’s life.

**Study limitations**

More extensive questionnaires like the Skindex and 36-Item Short Form Survey (SF-36) were not used to evaluate the QoL due to the poor compliance of patients and the relatively lengthy nature of those questionnaires.

**Conclusions**

NF1 has a significant effect on patients’ QoL due to changes in their appearance and societal stigma. Patients with comparatively fewer lesions can also experience a drastic impairment in their QoL, and their mental health must be considered just as much as a patient with extensive lesions. Early identification of patients with impaired QoL should prompt adequate therapeutic counseling and reference for a multidisciplinary approach.

**Appendices**

Dermatology Life Quality Index (DLQI) questionnaire
DERMATOLOGY LIFE QUALITY INDEX (DLQI) - INSTRUCTIONS FOR USE

The Dermatology Life Quality Index questionnaire is designed for use in adults, i.e. patients over the age of 16. It is self-explanatory and can be simply handed to the patient who is asked to fill it in without the need for detailed explanation. It is usually completed in one or two minutes.

SCORING

The scoring of each question is as follows:

- Very much: scored 3
- A lot: scored 2
- A little: scored 1
- Not at all: scored 0
- Not relevant: scored 0
- Question 7, “prevented work or studying”: scored 3

The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

HOW TO INTERPRET MEANING OF DLQI SCORES

- 0 – 1: no effect at all on patient’s life
- 2 – 5: small effect on patient’s life
- 6 – 10: moderate effect on patient’s life
- 11 – 20: very large effect on patient’s life
- 21 – 30: extremely large effect on patient’s life

REFERENCES

Finlay AY and Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-216.

Saara MK, Fenech R, Gatt RM, Salek MS and Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159:997-1035.

Hongbo Y, Thomas CL, Harrison MA, Salek MS and Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2003; 120:659-64.

There is more information about the DLQI, including over 85 translations, at www.dermatology.org.uk. The DLQI is copyright but may be used without seeking permission by clinicians for routine clinical purposes. For other purposes, please contact the copyright owners.

FIGURE 1: Dermatology Life Quality Index (DLQI) questionnaire (interpretation).
FIGURE 2: Dermatology Life Quality Index (DLQI) questionnaire.

**DERMATOLOGY LIFE QUALITY INDEX (DLQI)**

Hospital No: ................................................. Date: ............................
Name: .......................................................... Score: .............................
Address: ......................................................................... Diagnosis: ..........................

The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please tick (✓) one box for each question.

1. Over the last week, how itchy, sore, painful or stinging has your skin been?
   - Very much
   - A lot
   - A little
   - Not at all

2. Over the last week, how embarrassed or self conscious have you been because of your skin?
   - Very much
   - A lot
   - A little
   - Not at all

3. Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden?
   - Very much
   - A lot
   - A little
   - Not at all

4. Over the last week, how much has your skin influenced the clothes you wear?
   - Very much
   - A lot
   - A little
   - Not at all

5. Over the last week, how much has your skin affected any social or leisure activities?
   - Very much
   - A lot
   - A little
   - Not at all

6. Over the last week, how much has your skin made it difficult for you to do any sport?
   - Very much
   - A lot
   - A little
   - Not at all

7. Over the last week, has your skin prevented you from working or studying?
   - Yes
   - No

   If "No", over the last week, how much has your skin been a problem at work or studying?
   - A lot
   - A little
   - Not at all

8. Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?
   - Very much
   - A lot
   - A little
   - Not at all

9. Over the last week, how much has your skin caused any sexual difficulties?
   - Very much
   - A lot
   - A little
   - Not at all

10. Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?
    - Very much
    - A lot
    - A little
    - Not at all

Please check you have answered EVERY question. Thank you.

Additional Information

Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. Research and Recognition Committee, Dr. D. Y. Patil Medical College, Hospital and Research Centre issued approval IESC/PGS/2019/43. The Research and Recognition Committee, under the Faculty of Medicine, at its meeting held on 8th November 2019, has approved the research. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Griffiths CEM, Creamer D, Barker J, Chaimers R, Bleiker T: Rook’s Textbook of Dermatology, 9th Edition . Wiley, Hoboken, New Jersey; 2016. https://www.google.co.in/books/edition/Rook_s_Textbook_of_Dermatology/EyypCwAAQBAJ?hl=en.
2. Purkait R, Samanta T, Thakur S, Dhar S: Neurocutaneous syndrome: a prospective study . Indian J Dermatol.
3. Klein-Tasman BP, Colon AM, Brei N, et al.: Adaptive behavior in young children with neurofibromatosis type 1. Int J Pediatr. 2013, 2013:690432. 10.4103/0019-5154.84721
4. Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR: Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012, 14:977-82. 10.1038/gijm.2012.85
5. Pasini A, Lo-Castro A, Di Carlo L, Pitzianni M, Siracusano M, Rosa C, Galasso C: Detecting anxiety symptoms in children and youths with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet. 2012, 159B:869-73. 10.1002/ajmg.b.32095
6. Foji S, Mohammadi E, Sanagoo A, Jozubari L: The patients' experiences of burden of neurofibromatosis: a qualitative study. Iran J Nurs Midwifery Res. 2021, 26:542-8. 10.4103/ijnmr.IJNMR_178_20
7. Hay RJ, Johns NE, Williams HC, et al.: The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014, 134:1527-34. 10.1038/jid.2013.446
8. Wolkenstein P, Durand-Zaleski I, Moreno JC, Zeller J, Hemery F, Revuz J: Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol. 2001, 137:1421-5. 10.1001/archderm.137.11.1421
9. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994, 19:210-6. 10.1111/j.1365-2230.1994.tb01167.x
10. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY: The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008, 159:997-1055. 10.1111/j.1365-2133.2008.08832.x
11. Kodra Y, Thomas CI, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: what do dermatology life quality index scores mean?. J Invest Dermatol. 2005, 125:659-64. 10.1111/j.0022-202X.2005.23621.x
12. Lakshmanan A, Bubna AK, Sankarasubramaniam A, Veeraraghavan M, Rangarajan S, Sundaram M: A clinical study of neurofibromatosis-1 at a tertiary health care centre in south India. Pigment Int. 2016, 3:102-7. 10.4103/2349-5847.196502
13. Hudson SM, Harper PS, Compton DA: Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988, 111:1355-81. 10.1093/brain/111.6.1355
14. McGaughran J, Harris D, Donnai D, et al.: A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999, 36:197-203.
15. Friedman JM, Birch PH: Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. 1997, 70:138-45. 10.1002/(sici)1096-8628(19970516)70:2<138::aid-ajmg7>3.0.co;2-u
16. Kodra Y, Giustini S, DiVona L, Porciello R, Calvieri S, Wolkenstein P, Taruscio D: Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 2009, 218:215-20. 10.1159/000187594
17. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P: Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006, 140A:1983-9. 10.1002/ajmg.a.31422
18. Bicudo NP, de Menezes Neto BF, da Silva de Avó LR, Germano CM, Melo DG: Quality of life in adults with neurofibromatosis 1 in Brazil. J Genet Couns. 2016, 25:1063-74. 10.1002/jgen.10897-016-9959-8
19. Sanagoo A, Jozubari L, Koohi F, Sayehmiri F: Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol. 2019, 19:123. 10.1186/s12883-019-1538-v
20. Lai J, Beumont H, Jensen S: Quality of life for patients with neurofibromatosis type 1 associated plexiform neurofibromas (PNF). Value Health. 2017, 20:727. 10.1016/j.jval.2017.08.1970
21. Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C: Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neurooncol Adv. 2020, 2:1144-9. 10.1093/noajnl/vdaa003